Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

DenmarkBack to Denmark

Clinical trials in Silkeborg – page 5

687 clinical trials in Silkeborg, Denmark across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

DenmarkOur site in DenmarkKliniske-Forsoeg.dk(opens in a new tab)
Silkeborg at a glance
687
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

687 trials in Silkeborg

Open in trial search

Cardiac amyloidosis

Recruiting

Long‑Term Study of Acoramidis on Heart Function and Amyloid Burden in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR‑CM)

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Acoramidis
  • Sponsor:Eidos Therapeutics Inc.

Lipoprotein (a) increased

Recruiting

Phase 2 study of MK-7262 and enlicitide decanoate in adults with high lipoprotein(a)

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Enlicitide decanoate
  • Sponsor:Merck Sharp & Dohme LLC

Idiopathic pulmonary fibrosis

Recruiting

Phase IIb Study of AZD8965 versus Placebo in Adults with Idiopathic Pulmonary Fibrosis

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:AZD8965
  • Sponsor:AstraZeneca AB

Type 2 diabetes mellitus

Recruiting

Randomized trial of elecoglipron with dapagliflozin versus placebo in adults with type 2 diabetes mellitus and impaired renal function

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Cholangitis sclerosing

Recruiting

A Phase III Study of Elafibranor in Adults with Primary Sclerosing Cholangitis to Assess Efficacy and Safety

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Elafibranor
  • Sponsor:Ipsen Bioscience Inc.

Type IIa hyperlipidaemia

Recruiting

Zodasiran for Adolescents With Homozygous Familial Hypercholesterolemia: A Phase 3 Study of Efficacy and Safety

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:Zodasiran
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Osteosarcoma

Recruiting

Cabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Institut Gustave Roussy

Plasma cell myeloma

Recruiting

Cevostamab, Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 1‑3 Lines of Therapy

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:F. Hoffmann-La Roche AG

Interstitial lung disease

Recruiting

Safety, Pharmacokinetics, and Exploratory Efficacy of BI 1015550 and Nerandomilast in Children and Adolescents Aged 2‑17 Years With Fibrosing Interstitial Lung Disease

Investigational
Countries:DenmarkDenmark
  • Participants:0–17 years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

Pancreatic carcinoma metastatic

Recruiting

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Incyte Corp.

Plasma cell myeloma refractory

Recruiting

Phase II Study of Teclistamab Plus Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma After 1–3 Prior Therapies

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Pomalidomide
  • Sponsor:Odense University Hospital

B-cell type acute leukaemia

Recruiting

Study of MK-1045 versus blinatumomab with tocilizumab in patients with relapsed or refractory B-cell acute lymphoblastic leukemia

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Denmark

The busiest research cities in the country

All 45 cities in Denmark

Clinical research in Silkeborg

What the registry says about research in the country

01 Pain Management & Anesthesia

Innovative research focusing on post-surgical pain management and anesthetic techniques, particularly studying the effectiveness of Popliteal Plexus Block in knee surgeries.

  • Post-surgical pain control
  • Local anesthetic optimization
  • Multimodal pain management

Studies evaluating different volumes of anesthetic agents to improve patient outcomes after orthopedic procedures.

02 Musculoskeletal Disorders

Comprehensive trials investigating treatments for various joint and muscle conditions, including hand osteoarthritis and Dupuytren Contracture.

  • Arthritis management
  • Joint mobility improvement
  • Novel therapeutic approaches

Research exploring both medication-based and surgical interventions for musculoskeletal conditions.

03 Chronic Disease Management

Advanced research into chronic conditions including COPD and Type 2 diabetes, with focus on screening and treatment optimization.

  • Respiratory health
  • Cardiovascular screening
  • Disease prevention strategies

Innovative approaches to managing long-term conditions through personalized treatment strategies.

Back to DenmarkAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.